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Abstract
Background: ME/CFS is characterized by debilitating fatigue in addition to other physical and
cognitive symptoms. It is estimated to affect over 800,000 adults in the U.S. ME/CFS often results
in diminished functionality and increased economic impact. The economic impact of an illness is
generally divided into two categories: direct and indirect costs. Despite high prevalence rates and
the disabling nature of the illness, few studies have examined the costs of ME/CFS at the individual
and societal level. In fact, of the four studies examining the economic impact of ME/ME/CFS only
two used a U. S. sample. The current study used community and tertiary samples to examine the
direct costs of ME/CFS.
Methods: Using archival data, Study 1 examined the direct cost of ME/CFS in a community-based
sample in Chicago. Study 2 estimated the direct cost of ME/CFS in a tertiary sample in Chicago.
Both Study1 and Study 2 assessed direct costs using office visit costs, medical test costs, and
medication costs.
Results: For Study 1, the annual direct total cost per ME/CFS patient was estimated to be $2,342,
with the total annual direct cost of ME/CFS to society being approximately $2 billion. In Study 2,
the annual direct was estimated to be $8,675 per ME/CFS patient, with the total annual direct cost
of ME/CFS to society being approximately $7 billion.
Conclusion: Using ME/CFS prevalence data of 0.42 and indirect costs estimates from Reynolds et
al. (2004), the direct and indirect cost of ME/CFS to society was estimated to be $18,677,912,000
for the community sample and $23,972,300,000 for the tertiary sample. These findings indicate that
whether or not individuals are recruited from a community or tertiary sample, ME/CFS imposes
substantial economic costs.
Background
According to Jason et al. [1], chronic fatigue syndrome
(CFS) affects over 800,000 adults in the United States.
This illness is has more recently been referred to as ME/
CFS (where ME stands for either Myalgic Encephalomyeli-
tis or Myalgic Encephalopathy). The prognosis for severely
afflicted patients with ME/CFS is poor [2,3]. The persistent
and debilitating nature of ME/CFS often results in a reduc-
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tion in work and family life activities, as well as an
increase in health care costs [4]. Because it becomes diffi-
cult for patients with ME/CFS to continue employment at
premorbid levels, many have little choice but to leave
their jobs. Indeed, Jason et al. [1] found that participants
with ME/CFS were more likely to be receiving disability
income, be unemployed, or be working part-time than
control participants. Similar findings of higher unemploy-
ment rates among patients with ME/CFS were found in
Bombardier and Buchwald [5]; McCrone, Darbishire,
Ridsdale, and Seed [6]; Reynolds, Vernon, Bouchery, and
Reeves [7] and Tiersky, DeLuca, Dhar, Jonson, and Lange
[8]. In addition to employment loss, patients with ME/
CFS often experience escalating costs of health care due to
the search for a more definitive diagnosis and treatment
[9].
The economic impact of an illness is typically examined in
terms of direct and indirect costs. The former refers to
direct medical costs including hospital, ambulatory, pre-
scription medications, over-the-counter medications, and
medical laboratory testing. Indirect costs include trans-
portation, work productivity losses, disability reimburse-
ments, loss of leisure or duties at home, or services
provided by family members, friends, or other informal
care providers [10]. Four studies have examined the eco-
nomic impact of ME/CFS, three of which use clinic-based,
or tertiary samples, and only two of those samples are
from the United States. McCrone et al. [6] examined both
direct and indirect costs and found a higher proportion of
medical service use and unemployment among the ME/
CFS group, as well as higher lost employment costs and
combined service costs for patients with ME/CFS in terti-
ary care settings in the United Kingdom. Using an Austral-
ian tertiary sample, Lloyd and Pender [11] estimated an
average cost of $9,436 per patient with ME/CFS, including
about AU $2,000 per patient in direct medical costs.
Extrapolating this figure to the population of Australia,
Lloyd and Pender [11] estimated that ME/CFS cost the
government in excess of $25 million and cost the Austral-
ian community approximately AU $59 million. Bombar-
dier and Buchwald [5] examined the direct cost of patients
with ME/CFS in the United States using patients from a
referral clinic. The estimated average annual expenditure
was $1,013 per ME/CFS patient. Reynolds et al. [7] used a
community-based sample from Wichita, Kansas to esti-
mate the indirect cost of ME/CFS. These authors estimated
that the annual total value of lost productivity in the
United States was $9.1 billion, or about $20,000 per indi-
vidual with ME/CFS.
The previous studies of the economic impact of ME/CFS
provide evidence of the financial burden placed on indi-
viduals and their families, as well as on society as a whole,
however, none of the previous studies have estimated
these costs using both community-based and tertiary sam-
ples. The purpose of Study 1 was to estimate the direct cost
of ME/CFS to individuals with the illness and society
using a community-based sample while Study 2 examined
direct costs using a tertiary sample.
Study 1
Method
Participants
The data in the community-based study were derived
from an epidemiologic study of ME/CFS that was carried
out in three stages between 1995 and 1998 (for more
details see Jason et al., [1]). In the first Stage, 18,675 adults
representing a stratified random sample were screened for
ME/CFS using a telephone survey. Of these participants,
780 of the respondents reported having six or more
months of fatigue. Those participants who screened posi-
tive for ME/CFS-like illness, based on the Fukuda et al.
[12] criteria and a control sample that screened negative
were invited back for Stage 2 to complete a structured psy-
chiatric interview. The Structured Clinical Interview for
DSM-IV (SCID) was used to assess current and lifetime
psychiatric diagnoses [13]. In Stage 3, a physician con-
ducted a detailed medical examination to rule out any
exclusionary medical conditions. A team of four physi-
cians and a psychiatrist made a final diagnosis for each
participant using the current US case definition of ME/
CFS [12]. Of the 213 participants who completed all three
Stages of the study, 47 were classified as having no fatigue,
45 were classified as having idiopathic chronic fatigue
(ICF), 89 had chronic fatigued explained by a medical or
psychiatric condition (CF-Explained), and 32 were diag-
nosed with ME/CFS.
The current study focused on the 47 no fatigue control
participants and the 32 participants diagnosed with ME/
CFS. During Stage 3, participants were asked to sign a
medical release form and provide the names of their pre-
vious physicians, as well as a copy of their previous med-
ical records. Our analyses relied on information in the
medical records and therefore participants were excluded
from the cost estimate if they did not provide complete
medical record data. Twenty-one of the ME/CFS partici-
pants and 24 of the controls provided a complete set of
medical records. To create a healthy comparison group,
the control participants were screened for any chronic
health conditions. According to participant medical
records, the only exhibited chronic conditions were
hypertension, diabetes, and hypothyroidism. For the pur-
poses of a healthy control group, participants in the no
fatigue group with one or more of these three illnesses
were excluded from these analyses. Following these exclu-
sions, 21 ME/CFS participants and 15 control participants
were included in cost estimates for this study. Sociodemo-
graphic information is provided in Table 1. Of the finalDynamic Medicine 2008, 7:6 http://www.dynamic-med.com/content/7/1/6
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sample of 36 participants, 13.9% were African American,
55.6% were Caucasian, 22.2% were Latino and 8.3%
reported other ethnicity. From this sample 61.1% were
females and 38.9% were males. Age of the participants
ranged from 20 to 64, with a mean age of 37.
Measures
CFS Screening Questionnaire
The CFS Screening Questionnaire, developed by Jason,
Ropacki, and Santoro [14], was administered to all partic-
ipants. In addition to screening for ME/CFS symptomol-
ogy, the questionnaire assessed sociodemographic
characteristics including current work status and socioeco-
nomic status variables. Specifically, participants were
asked if they were receiving disability income, were unem-
ployed, were working part-time, were working full-time,
or were retired. Participants who indicated that they were
currently employed were asked to provide information
about their current job, including hours of employment,
and preferred hours of employment, as well as about con-
ditions in their current work place. Information from this
questionnaire was used to assess work loss among partic-
ipants, as well as to examine differences in the amount of
time spent at work. Participants were also asked to report
about their disability including the need for help from a
professional to get employment accommodations, reduc-
tion in work activities, and difficulty performing work
activities.
The Medical Questionnaire
The Medical Questionnaire, a self-report measure, is a
modified version of the Chronic Fatigue Questionnaire
developed by Komaroff, Faglioli, and Geiger [15]. The
questionnaire was used to assess current and past medical
history including information about medication prac-
tices. Participants were asked to list their current usage of
medications (prescription and over-the-counter), reasons
for medications, and doses they were currently taking.
Previous medical record
In addition to the self-report measures, participants were
asked to provide a copy of previous medical records.
Table 1: Community Sample Characteristics
ME/CFS Group (N = 21) Control Group (N = 15)
N % N %
Race
African American 3 14.3 2 13.3
Caucasian 10 47.6 10 66.7
Latino 6 28.6 2 13.3
O t h e r 29 . 516 . 7
Sex
Women 14 66.7 8 53.3
Men 7 33.3 7 46.7
Education
Some or less than high school 2 9.5 0 0.0
High school degree or part college 9 42.9 6 40.0
Standard college degree 8 38.1 4 26.7
Graduate/professional degree 2 9.5 5 33.3
Occupation
Unskilled worker 3 14.3 2 13.3
Skilled worker 2 9.5 1 6.7
Clerical worker 4 19.0 2 13.3
Technician 4 19.0 2 13.3
Manager 6 28.6 6 40.0
Administrator 2 9.5 2 13.3
Age
18 – 29 7 33.3 3 20.0
30 – 39 4 19.0 7 46.7
40 – 49 7 33.3 4 26.7
5 0  –  5 9 29 . 516 . 7
60 – 69 1 4.8
Socioeconomic Status Scores
5 – 14 3 14.3 2 13.3
1 5  –  2 4 14 . 816 . 7
25 – 34 8 38.1 2 13.3
35 – 44 7 33.3 7 46.7
45 – 54 2 9.5 3 20.0Dynamic Medicine 2008, 7:6 http://www.dynamic-med.com/content/7/1/6
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These included the name, address, and phone number of
the participants' primary care physician, office visit dates
and notes, and medical test names, dates, and results.
Medical records were used to assess amount of medical
service use. For each participant, the most recent full year
of medical record information was used in the estimates.
Procedure
The objective of Study 1 was to estimate the economic
impact of ME/CFS on an individual and at the societal
level. The direct economic impact of ME/CFS was esti-
mated using current medication, medical test and medical
office visit prices. As part of the Medical Questionnaire,
each participant was asked to list the medications that
they were currently taking. Typical drug dosages and
quantity needed for a 30-day supply were calculated using
the  Physician's Desk Reference Monthly Prescribing Guide
[16]. Current drug prices were obtained using the Febru-
ary 2005 Update to the RedBook: Pharamacy's Fundamental
Reference [17]. The RedBook provides cost information for
prescription and over-the-counter medications. For each
drug, the RedBook gives the generic name, the active ingre-
dient, and the average wholesale price for various doses
and quantities of each medication. A monthly medication
cost was calculated for each participant. Each participant's
monthly cost was then multiplied by twelve and the prod-
ucts were averaged to estimate the annual cost of medica-
tion.
Medical test usage was another direct measure of the eco-
nomic cost of ME/CFS. Based on the most recent year of
medical records, specific medical tests received by each
participant were recorded. Current medical test prices
were obtained from two public Chicago hospitals. These
prices were the actual fee that the hospitals charged for the
tests, not accounting for different types of medical insur-
ance. The annual costs of medical tests were calculated
using the average prices from these two hospitals.
Costs for medical office visits were also included in the
direct estimate of the economic impact of ME/CFS. The
number of office visits per year was calculated by counting
the office visits documented in a year of medical record
data for each participant. The average cost of office visits
among established and new patients in the East North
Central region of the U.S., published in the American
Medical Association's Socioeconomic Characteristics of
Medical Practice was $76.55. This cost was used to calcu-
late the cost per participant per year for medical office vis-
its [18].
Annual costs of medication usage, medical tests, and med-
ical office visits were summed to calculate the average
total annual direct costs of patients with ME/CFS and for
comparison purposes, the control participants. This aver-
age sum of fees was considered the direct costs to individ-
uals with ME/CFS and their families. Societal level impact
was assessed by multiplying the total annual direct cost by
the estimated number of adults in the United States with
ME/CFS, using the prevalence rate of 0.42 published by
Jason et al. [1], or approximately 836,000 adults.
Results
Sociodemographic variables
Data from 36 participants, 21 participants with ME/CFS
and 15 control participants, were analyzed. The demo-
graphic characteristics of the community sample are
detailed in Table 1. There were no significant differences
between participants with ME/CFS and control partici-
pants for ethnicity, gender, education level, occupation,
age, or socioeconomic status. A significantly higher pro-
portion of participants with ME/CFS reported having to
cut down on the amount of time spent on work or other
related activities (M = .80) when compared to control par-
ticipants (M = .33; χ2(2, N = 35) = 10.02, p = .01). Partic-
ipants with ME/CFS (70%) reported more difficulty
performing work or other activities than controls
(13.3%), χ2(2, N = 35) = 13.10, p = .00. Participants with
ME/CFS were more likely to feel that they might need help
from a professional in order to receive employment
accommodations than controls (40% versus 0%, respec-
tively, χ2(2, N = 35) = 6.20, p = .05). A significantly higher
percentage of participants with ME/CFS than controls
were receiving disability income (19% vs. 0%), unem-
ployed (23.8% vs. 6.7%) or working part-time (19% vs.
6.7%). When current work status variables were collapsed
into two categories, working full-time and not working
full-time (including participants who reported working
part-time, being on disability, being unemployed, or
being retired), the differences between participants with
ME/CFS (33.3% were working full-time) and controls
(86.7% were working full-time) was significant, χ2(1, N =
36) = 10.10, p = .00.
Direct medical costs
Medication usage and costs were assessed in the estimate
of direct medical service use. Based on self-reported use
and physician exam information, the mean number of
prescription medications was 1.6 (SD = 2.1) for partici-
pants with ME/CFS and .7 (SD = .9) for control partici-
pants, however these differences were not statistically
significant, t(34) = 1.56, p = .13. The mean number of
over-the-counter medications was .4 (SD = .6) for partici-
pants with ME/CFS and .1 (SD = .4) for controls, and these
differences were not significant, t(33) = 1.57, p = .13. The
total average annual cost of prescription and over-the-
counter medications was significantly higher for partici-
pants with ME/CFS ($1,159; SD = 1426) than for controls
($321; SD = 415), t(25) = 2.55, p = .02.Dynamic Medicine 2008, 7:6 http://www.dynamic-med.com/content/7/1/6
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Medical test and medical office visit costs were also
included in the direct estimate of economic impact.
According to medical record information, the mean
number of medical tests received by participants with ME/
CFS was 3.2 (SD = 3.3) and 2.0 (SD = 2.9) for control par-
ticipants. These means were not significantly different,
t(34) = 1.16, p = .25. Annual medical tests on average cost
participants with ME/CFS $713 (SD = 1200) and control
participants $470 (SD = 856), but these differences were
not statistically significant, t(34) = .67, p = .51. Based on
medical record data, the mean number of office visits per
year was 6.1 (SD = 3.6) for participants with ME/CFS and
4.5 (SD = 3.4) for control participants, but these differ-
ences were not statistically significant, t(34) = 1.42, p =
.17. Participants with ME/CFS spent an average of $470
(SD = 274) on medical office visits, while control partici-
pants spent an average of $342 (SD = 259). These cost
were not statistically significant, t(34) = 1.42, p = .17. The
total annual direct costs, using the mean sum of medica-
tion, medical test, and medical office visit costs, for partic-
ipants with ME/CFS was $2,342 (SD = 2174) and for
controls was $1,133 (SD = 1262), which approached sig-
nificance, t(34) = 1.93, p = .06.
Total costs
This total direct cost was extrapolated to the adult popula-
tion of the U.S. as a whole to estimate the direct societal
cost implications. We used Jason et al.'s (1999) prevalence
estimates (.42) and the US Census 2000 population esti-
mates (836,000 adults with ME/CFS). The estimated total
annual direct cost of ME/CFS to society was $1,
957,912,000 ($2,342 × 836,000) or approximately $2 bil-
lion.
Study 2
Method
Participants
For the tertiary sample, 114 individuals were recruited:
46% were referred by physicians, 34% were recruited by
media (newspapers, TV, radio, etc.), and 20% stemmed
from other sources (e.g., heard about the study from a
friend, family member, person in the study, etc.). There
were no significant demographic differences for patients
recruited from these varying sources. Twenty-four addi-
tional individuals who were screened were excluded due
to a variety of reasons (i.e., lifelong fatigue, less than 4
Fukuda symptoms, BMI > 45, melancholic depression or
bipolar depression, alcohol or substance abuse disorder,
autoimmune thyroiditis, cancer, lupus, rheumatoid
arthritis). Approaches to reduce attrition included use of
letters and telephone reminders of all appointments, flex-
ibility regarding working around vacations and medical
and other crises, reimbursement for transportation costs,
and participant honoraria.
All participants were required to be at least 18 years of age,
not pregnant, able to read and speak English, and consid-
ered to be physically capable of attending the scheduled
sessions. Bedridden and wheelchair bound patients were
excluded due to the practical difficulties of making
appointments. Referrals to local physicians who treat ME/
CFS and to support groups were offered to these individu-
als. After a consent form was filled out, participants were
provided a thorough medical and psychiatric examina-
tion, similar to what was described above for the commu-
nity based sample.
Measures
CFS Screening Questionnair
The CFS Screening Questionnaire [14] was used to screen
for ME/CFS symptoms and assess sociodemographic char-
acteristics.
Client Service Receipt Inventory
The Client Service Receipt Inventory (CSRI) is an instru-
ment that measures the cost of psychiatric interventions
[19]. This has been adapted for use in estimating cost
information for ME/CFS [6]. As part of the CSRI, partici-
pants provided details of services they have used in the
previous 3 months, including general practitioners, other
primary care services; in-patient hospital care; other med-
ical physicians; osteopaths; chiropractors; physiothera-
pists; and acupuncturist/homeopaths. For each of these
different services participants provided details including
duration of contact and reason for visits. Finally, partici-
pants estimated the amount they have paid out-of-pocket
for health care relating to their fatigue.
Procedure
Results
Sociodemographic variables
Data were analyzed from the 90 of the 114 participants
with ME/CFS who had full economic information. The
demographic characteristics of the tertiary sample are
detailed in Table 2. The majority of the sample was Cau-
casian and female. Seventy-six percent of participants in
the tertiary sample reported having to cut down on their
work and related activities. Of the respondents in this
sample, 27.6% stated that they were receiving disability,
21.8% were unemployed, 26.4% were working part-time,
and 25.3% were working full-time.
Direct costs
Medication usage and costs were estimated for direct med-
ical service use. Based on self-reported use and physician
examination information, the mean number of prescrip-
tion medications was 3.7 (SD = 3.5). The mean number of
over-the-counter medications was 2.2 (SD = 2.3). The
total average annual cost of prescription and over-the-
counter medications for this sample was much higherDynamic Medicine 2008, 7:6 http://www.dynamic-med.com/content/7/1/6
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than the community or control sample, $5,447 (SD =
5,051). Medical test and medical office visit costs were
also included in the direct estimate of economic impact.
The mean number of medical tests was 6.4 (SD = 9.5).
Medical tests cost $2,999 on average (SD = 7,026), while
the mean number of office visits per year was 6.3 (SD =
4.4). Office visits cost an average of $228 (SD = 333). The
total annual direct cost was estimated using the mean sum
of medication, medical test, and medical office visit costs.
The total annual direct cost was $8,675 (SD = 8,854). This
is nearly three times the cost of the community sample in
Study 1.
The estimated total annual direct cost of ME/CFS to soci-
ety is ($8,675 × 836,000 = $7,252,000,000) or approxi-
mately $7 billion.
Discussion
These findings suggest that there is a high economic cost
associated with ME/CFS for patients, their families, and
for society as a whole. This study has provided a conserv-
ative estimate of the direct economic impact of ME/CFS,
with a mean annual cost of $2,342 to $8,675 per patient.
When extrapolated to the U.S., the direct cost to the Amer-
ican health care system is estimated to be from $1,
957,912,000 to 7,252,000,000.
In other words, the total annual direct estimated costs for
the tertiary sample were nearly three times the cost of the
community sample.
It is at least possible that these differences might have
been due to the differing characteristics of the sample. In
study 1, the majority of participants with ME/CFS were
minorities, whereas in study 2, 90% were Caucasian.
There were also differences in the educational attainment
between the two samples. Among those with ME/CFS in
study 1, only 48% had at least standard college degree,
whereas among those is study 2, 71% had this level of
educational attainment. Finally, the majority of those in
study 1 had never been diagnosed with ME/CFS, whereas
all of those participants in study 2 had this diagnosis. Very
possibly, those participants with ME/CFS in study 1 had
less resources to devote to medical care, and the majority
did not even know that had this illness. In contrast, all of
those in study 2 had a ME/CFS diagnosis, and they had
possibly had more resources to invest in the medical diag-
nosis and treatment of this illness. These data suggest that
the economic cost of ME/CFS will vary between those in
community-based samples who might not have been
diagnosed and those in tertiary clinics, who might have a
diagnosis and more resources, and these differences may
influence the societal cost of ME/CFS.
These economic losses can have a substantial long-term
impact on ME/CFS patients' standard of living and quality
of life. With high unemployment rates among ME/CFS
patients, the direct cost of medical services could become
even more problematic to individuals and families due to
a loss of health insurance benefits and thus, increases in
out-of-pocket medical expenses. Our estimate of the direct
cost of medical expenses was $2,342 to $8,675 per ME/
CFS patient. This estimate is not directly comparable to
previous estimates of the direct cost of ME/CFS due to dif-
ferent sampling strategies. Bombardier and Buchwald [5]
estimated an average annual medical expenditure of
$1,031 per ME/CFS patient. Estimates from Lloyd and
Pender [11] and McCrone et al. [6] used samples from
Australia and the U.K. respectively, and due to different
health care systems and prevalence rates, are not directly
comparable with the current estimate. In addition, these
studies had a number of other differences that might
account for the varying cost estimates (e.g., use of different
diagnostic criteria and definitions; differential levels of
severity of ME/CFS symptoms and other comorbidities).
In addition to the direct medical costs imposed on indi-
viduals and society, there is also a substantial economic
Table 2: Tertiary Sample Characteristics
(N = 90)
Na %
Race
African American 4 4.5
Caucasian 80 89.9
Latino 4 4.5
Other 1 1.1
Sex
Women 75 83.3
Men 15 16.7
Education
Some or less than high school 1 1.1
High school degree or part college 25 27.8
Standard college degree 44 48.9
Graduate/professional degree 20 22.2
Age
18 – 29 9 10
30 – 39 21 23.3
40 – 49 27 30
50 – 59 24 26.7
60 – 70+ 9 10
Socioeconomic Status Scores
5 – 14 33 41.3
15 – 24 4 5.0
25 – 34 11 13.8
35 – 44 19 23.8
45 – 54 13 16.3
aNote. Values not equaling 90 participants signify missing data.Dynamic Medicine 2008, 7:6 http://www.dynamic-med.com/content/7/1/6
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costs related to lost productivity. Participants with ME/
CFS were receiving more disability benefits, and were
more likely to be unemployed or working part-time than
their control counterparts. Indirect costs to the individual
and society can be estimated according to a study con-
ducted by Reynolds et al., [7]. According to their study,
approximately one third of patients with ME/CFS, who in
other circumstances would have participated in the work
force, stopped working and for those who continued
working, their income was cut by a third. This change in
employment status represented an estimated annual loss
of $20,000.
Although our data did not include salary variables and
indirect costs could only be examined in terms of work
status change and increased disability, we could apply the
Reynolds [7] figure ($20,000) to our sample. For study 1,
using estimates from Reynolds et al. [7], we could esti-
mate that the annual indirect cost to society to be
$16,720,000,000 (836,000 × $20,000) or almost $17 bil-
lion. Together the total indirect and direct costs to society
could be estimated to be $18,677,912,000, or over 18 and
a half billion dollars. For study 2, the estimated total
annual indirect cost to society is 836,000 × $20,000 =
$16,720,000,000. Therefore, in study 2, together the total
indirect and direct costs to society equals
$23,972,300,000 or close to 24 billion dollars. For studies
1 and 2, the total direct and indirect costs due to ME/CFS
were estimated to range from 17 to 24 billion dollars.
When interpreting the findings from the current study,
some limitations should be considered. First, our study
relied on archival data, and therefore did not include
some information that would have been helpful in esti-
mating the economic impact. For example, we did not
have an estimate of salary or a measure of the actual
number of work hours lost. According to McCrone et al.
[6], an important variable in estimating the indirect cost is
the role of informal care providers. Informal care provid-
ers refer to friends or relatives that help care for the patient
without remuneration, but still incur an opportunity cost.
Our archival data did not include variables to estimate
these types of financial losses. Therefore, we could not cal-
culate costs due to lost productivity, and estimating a spe-
cific indirect cost was impossible. Another limitation to
the archival data is that participants in the community
based sample provided their medical records and com-
pleted the self-report questionnaires between 1995 and
1997. Participants infrequently listed alternative medica-
tions (herbs or supplements) or treatments (acupuncture)
that are more commonly used now, but likely were not
frequently used 10 years ago. Participant medical record
information also did not include information about hos-
pital stays or ambulatory use. Therefore, our estimates of
the direct costs of ME/CFS are likely an underestimate
because they do not include these types of service use.
In addition, current medication usage information relied
on participant recall of service use, and therefore may not
be accurate. However, corroboration of participant medi-
cation use was obtained by the examining physician for
more than three quarters of the participants in Study 1.
Also, other means of data collection besides self-report
data were analyzed. The use of medical records likely pro-
vided an accurate indication of number of office visits and
medical test usage. However, medical records were not
available for participants in Study 2. These limitations
should be addressed in future research. Ideally, estimates
of the economic impact of ME/CFS should include esti-
mates of both direct and indirect costs.
This study suggests that the direct costs of this illness are
incurred variously, both by the individual patient and by
society. For the community group, the prices of prescrip-
tions and medical services and tests are calculated, but we
were not able to determine what portion was covered by
insurance and what part was paid out-of pocket. Further-
more, comparison to the control group shows that while
the ME/CFS group spends more the total annual direct
costs (the mean sum of medication, medical test, and
medical office visit costs; $2,342 versus $1,133), this dif-
ference only approached significance at the .06 level.
More research is clearly needed to be able to answer
whether health insurance premiums are more costly on
average to those with ME/CFS. It is certainly possible that
the direct costs to individuals, primarily deductibles,
might be less than estimated. It is also possible that there
might be added costs of this illness to the medical indus-
try, but more information is needed concerning retail
prices-per-unit in order to calculate industry costs.
In conclusion, Jason et al. [1] estimates that more than
800,000 adults in the United States have ME/CFS. This fig-
ure combined with cost information reported in the cur-
rent study suggests that ME/CFS has substantial economic
costs, whether one uses samples recruited from the com-
munity or from a tertiary care clinic. These cost estimates
in combination with high prevalence rates are some of the
reasons that more research into the cause, effective diag-
nosis, and treatment are necessary.
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